Chronic spontaneous urticaria in patients over 65 years old

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

AIM: To study clinical and immunological features in chronic spontaneous urticaria patients aged 65+ and 18–65 yo.

MATERIALS AND METHODS: In total, the study included 494 adult patients with chronic spontaneous urticaria (CSU), who were under our supervision from 2014 to 2019. Depending on the age, the patients were divided into 2 groups according to their age: group 1 included patients over 65 years old (51 subjects, 10.3%); group 2 – patients 18–65 years old (443 subjects, 89.7%). In patients with CSU, angioedema was found with the same frequency regardless of age (group 1 – in 49% of patients, in group 2 – in 58.3%). Female were predominated in both groups (90.2% in the 1st and 85.1% in the 2nd). The duration of CSU exceeding 5 years was less common in elderly patients (in group 1 – 6.8%, in group 2 – 17.7%; p<0.05).

RESULTS: The duration of CSU ranges from 1 to 5 years in most patients regardless of age. The combination of CSU with inducible urticaria is not typical for patients over 65 years old. The analysis of comorbid pathology showed that diabetes mellitus is significantly more common and, less often – autoimmune thyroiditis and allergic rhinitis in patients over 65 years old, in comparison with patients aged 18–65 years old. The influence of the age of patients with CSU on IgG, IgM, IgA, CRP levels in blood serum has not been established. The level of total IgE was significantly lower in patients of the elder age group in comparison with the 2nd group (84.1±18.44 IU/ml and 114.9±11.0 IU/ml; p<0.05, respectively).

CONCLUSION: It is registered that 1/10 of the adult patients with CSU are over 65 years old, and the duration of the disease in them rarely exceeds 5 years. The features of the comorbid pathology in this category of patients have been revealed. The difference in the content of total IgE in patients of different age groups is shown here.

Full Text

Restricted Access

About the authors

Raisa Ya. Meshkova

Smolensk State Medical University

Email: meshkova.raisa@yandex.ru
ORCID iD: 0000-0002-7806-9484

Head of the Department of Clinical Immunology and Allergology, MD, PhD, Professor

Russian Federation, Smolensk

Aleksandr V. Vitchuk

Smolensk State Medical University

Author for correspondence.
Email: Djonnyfunt@mail.ru
ORCID iD: 0000-0003-4814-3847

Assistant of the Department of Clinical Immunology and Allergology

Russian Federation, Smolensk

Svetlana A. Aksenova

Smolensk State Medical University

Email: Aksenova7@yandex.ru
ORCID iD: 0000-0003-1539-6709

Assistant Professor of the Department of Clinical Immunology and Allergology

Russian Federation, Smolensk

Victoria V. Bitutskaya

Clinical Hospital № 1, Smolensk Regional Center of Allergology and Immunology

Email: Bjfs@mail.ru

Allergist-Immunologist

Russian Federation, Smolensk

Elena V. Volkova

Clinical Hospital № 1, Smolensk Regional Center of Allergology and Immunology

Email: docvolkova@mail.ru

Allergist-Immunologist, Head of the Clinical Hospital № 1

Russian Federation, Smolensk

Natalya V. Kovrigina

Smolensk State Medical University

Email: Kovriginanv@mail.ru
ORCID iD: 0000-0002-2805-8138

Assistant of the Department of Clinical Immunology and Allergology

Russian Federation, Smolensk

Elena V. Slabkaya

Smolensk State Medical University

Email: Slabkaja@yandex.ru
ORCID iD: 0000-0003-0500-3625

Assistant Professor of the Department of Clinical Immunology and Allergology, 

Russian Federation, Smolensk

References

  1. Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria // Allergy. 2018. Vol. 73. N 7. P. 1393–1414. doi: 10.1111/all.13397
  2. Данилычева И.В., Ильина Н.И., Лусс Л.В. и соавт. Федеральные клинические рекомендации. Крапивница // Российский Аллергологический Журнал. 2018. Т. 15. № 5. С. 47–62.
  3. Magerl M., Altrichter S., Borzova E., et al. The definition, diagnostic testing, and management of chronic inducible urticarias – The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision // Allergy. 2016. Vol. 71. N 6. P. 780–802. doi: 10.1111/all.12884
  4. Kaplan A. Diagnosis, pathogenesis, and treatment of chronic spontaneous urticaria // Allergy Asthma Proc. 2018. Vol. 9. N 3. P. 184–190. doi: 10.2500/aap.2018.39.4121
  5. Maurer M., Houghton K., Costa C., et al. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study // World Allergy Organ J. 2018. Vol. 11. N 1. P. 32.doi: 10.1186/s40413-018-0216-1
  6. Chuamanochan M., Kulthanan K., Tuchinda P., et al. Clinical features of chronic urticaria in aging population // Asian Pac J Allergy Immunol. 2016. Vol. 34. N 3. P. 201–205.doi: 10.12932/AP0708
  7. Ban G.Y., Kim M.Y., Yoo H.S., et al. Clinical features of elderly chronic urticaria // Korean J Intern Med. 2014. Vol. 29. N 6. P. 800–806. doi: 10.3904/kjim.2014.29.6.800
  8. Lee N., Lee J.D., Lee H.Y., et al. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010–2014 // Allergy Asthma Immunol Res. 2017. Vol. 9. N 5. P. 438–445. doi: 10.4168/aair.2017.9.5.438
  9. Maurer M., Raap U., Staubach P., et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study // Clin Exp Allergy. 2019. Vol. 49. N 5. P. 655–662.doi: 10.1111/cea.13309
  10. Saini S., Kaplan A. Chronic spontaneous urticaria: The Devil’s Itch // J Allergy Clin Immunol Pract. 2018. Vol. 6. N 4. P. 1097–1106. doi: 10.1016/j.jaip.2018.04.013
  11. Balp M.M., Weller K., Carboni C., et al. Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients // Pediatr Allergy Immunol. 2018. Vol. 29. N 6. P. 630–636. doi: 10.1111/pai.12910
  12. Magen E., Mishal J., Schlesinger M. Clinical and laboratory features of chronic idiopathic urticaria in the elderly // Int J Dermatol. 2013. Vol. 52. N 11. P. 1387–1391.doi: 10.1111/ijd.12109
  13. Kolkhir P., André F., Church M., et al. Potential blood biomarkers in chronic spontaneous urticaria // Clin Exp Allergy. 2017. Vol. 47. N 1. P. 19–36. doi: 10.1111/cea.12870
  14. Sastre J. Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience // J Investig Allergol Clin Immunol. 2020. Vol. 30. N 3. P. 156–168. doi: 10.18176/jiaci.0401
  15. Van Rooij J., Schiemaker H.C., Bruno R., et al. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine // Br J Clin Pharmacol. 1993. Vol. 35. N 6. P. 661–663.doi: 10.1111/j.1365-2125.1993.tb04199.x
  16. Moss A.J., Chaikin P., Garcia J.D., et al. A review of the cardiac systemic side-effects of antihistamines: ebastine // Clin Exp Allergy. 1999. Vol. 29. S. 3. P. 200–205.doi: 10.1046/j.1365-2222.1999.0290s3200.x
  17. Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults // Drugs. 1996. Vol. 52. S. 1. P. 30–34. doi: 10.2165/00003495-199600521-00008
  18. Chaikin P., Gillen M.S., Malik M., et al. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects // Br J Clin Pharmacol. 2005. Vol. 59. P. 346–354.doi: 10.1111/j.1365-2125.2005.02348.x
  19. Sánchez J., Zakzuk J., Cardona R. Prediction of the efficacy of antihistamines in chronic spontaneous urticaria based on initial suppression of the histamine-induced wheal // J Investig Allergol Clin Immunol. 2016. Vol. 26. N 3. P. 177–184.doi: 10.18176/jiaci.0039
  20. Peyri J., Vidal J., Marrón J., et al. Ebastine in chronic urticaria: a double-blind placebo controlled study // J Dermatol. 1991. Vol. 2. N 2. P. 51–53. doi: 10.3109/09546639109086774
  21. Godse K. Ebastine in chronic spontaneous urticaria in higher doses // Indian J Dermatol. 2011. Vol. 56. N 5. P. 597–598. doi: 10.4103/0019-5154.87168
  22. Magerl M., Schmolke J., Siebenhaar F., et al. Acquired cold urticaria symptoms can be safely prevented by ebastine // Allergy. 2007. Vol. 62. N 12. P. 1465–1468.doi: 10.1111/j.1398-9995.2007.01500.x

Supplementary files

Supplementary Files
Action
1. Figure. Concentration of IgE in blood serum of patients with HSC

Download (62KB)
2. Table 3. Results of a clinical study of the therapeutic efficacy of ebastine in chronic urticaria, according to multicenter studies [20]

Download (313KB)

Statistics

Views

Abstract: 134

PDF (Russian): 2

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright © Pharmarus Print Media, 2021



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies